Clinical Trials · NCT00309283

Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study

CompletedPhase 3Octreotide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Mario Negri Institute for Pharmacological Research
Enrollment
78
Start date
Apr 2006
Locations
5 sites, Italy
Primary endpoint
Change over baseline of the total kidney volume at 1 and 3 years follow-up (estimated by gadolinium contrast enhanced and T2-weighted magnetic resonance imaging, MRI).
View Octreotide compound reference